CAFE Comparison of Atypicals in First Episode of Psychosis

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: University of North Carolina
• Treatments: Olanzapine; Risperidone

Criteria

Inclusion Criteria:

• Patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 1-60 months

• Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months)

• Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics

Exclusion Criteria:

• Patients with history of psychotic disorder with recovery period of at least 3 months

• Female patients who are pregnant or nursing

• Patients with a known history of mental retardation